Multi-Pathway Microenvironment Regulation for Atherosclerosis Therapy Based on Beta-Cyclodextrin/L-Arginine/Au Nanomotors with Dual-Mode Propulsion
Multi-Pathway Microenvironment Regulation for Atherosclerosis Therapy Based on Beta-Cyclodextrin/L-Arginine/Au Nanomotors with Dual-Mode Propulsion
复制标题
基于β-环糊精/L-精氨酸/Au双模式推进纳米电机的多途径微环境调节动脉粥样硬化治疗
作者：
Wu Z;Wu R;Li X;Wang X;Tang X;Tan K;Wan M;Mao C;Xu X;Jiang H;Li J;Zhou M;Shi D
目前大多数动脉粥样硬化（AS）的非药物治疗策略对斑块的渗透性较差，并且仅针对其形成过程中的某个因素，导致治疗效果有限。本文通过β-环糊精（β-CD）和L-精氨酸（LA）的共价结合和自组装，并固定Au纳米粒子，构建了一种具有双模推进功能的纳米粒子，该纳米粒子对AS位点的活性氧（ROS）和近红外（NIR）激光敏感。近红外激光照射可用作驱动力，并通过光热效应消融炎性巨噬细胞。由纳米马达释放的一氧化氮（NO）可以用作另一种驱动力和治疗剂，以促进斑块部位的内皮修复。LA可以清除炎症部位的ROS，β-CD可以促进泡沫细胞中胆固醇的清除。特别是，纳米马达的两种驱动模式协同促进它们在斑块中的聚集和渗透。这种纳米颗粒可以通过多种方式调节AS的微环境，包括内皮修复、脂质清除和降低ROS的联合治疗，有望成为治疗AS的潜在非药物策略。
Most of the current non‐pharmacological treatment strategies for atherosclerosis (AS) suffer from poor penetration into the plaque and only aim at a certain factor in its formation process, resulting in limited therapeutic effect. Herein, a kind of nanomotor with dual‐mode propulsion is constructed, which is sensitive to higher reactive oxygen species (ROS) at the AS site and near‐infrared (NIR) laser by the covalent binding and self‐assembly of β‐cyclodextrin (β‐CD) and L‐arginine (LA) with immobilization of Au nanoparticles. NIR laser irradiation can be used as a driving force and to ablate inflammatory macrophages through the photothermal effect. The nitric oxide (NO) released by the nanomotors can be used as another driving force and a therapeutic agent to promote endothelial repair in the plaque site. LA can eliminate ROS in the inflammatory site, and β‐CD can promote the removal of cholesterol from foam cells. In particular, the two driving modes of nanomotors synergistically promote their aggregation and penetration in the plaque. This kind of nanomotor can regulate the microenvironment of AS in multiple ways, including combination therapy for endothelial repair, lipid clearance, and reducing ROS, which is expected to become a potential non‐pharmacological strategy in the treatment of AS.